Peroxisome proliferator–activated receptor α (PPAR α) is a nuclear receptor of clinical
interest as a drug target in various metabolic disorders. PPAR α also exhibits marked anti …

Diabetic retinopathy (DR) causes significant visual loss on a global scale. Treatments for the
vision-threatening complications of diabetic macular edema (DME) and proliferative diabetic …

Diabetic macular oedema, characterised by exudative fluid accumulation in the macula, is
the most common form of sight-threatening retinopathy in people with diabetes. It affects one …

There is a global diabetes epidemic correlating with an increase in obesity. This coincidence
may lead to a rise in the prevalence of type 2 diabetes. There is also an as yet unexplained …

The Wnt signaling pathway plays a pivotal role in vascular morphogenesis in various organs
including the eye. Wnt ligands and receptors are key regulators of ocular angiogenesis both …

Peroxisome proliferator-activated receptor α (PPARα) is a ligand-activated transcription
factor that is involved in lipid metabolism of various tissues. Different metabolites of fatty …

Fenofibrate, a specific agonist of peroxisome proliferator–activated receptor-α (PPARα),
displays robust therapeutic effects on diabetic retinopathy (DR) in patients with type 2 …

Diabetes mellitus (DM) ranks seventh as a cause of death worldwide. Chronic
complications, including cardiovascular, renal, and eye disease, as well as DM-associated …

Fenofibrate (FF), as a peroxisome-proliferator-activated receptor α (PPARα) agonist, has
been used clinically for decades to lower lipid levels. In the present study, we examined …

Fenofibrate is a peroxisome proliferator-activated receptor α (PPARα) agonist and has been
shown to have therapeutic effects on diabetic retinopathy (DR). However, the effects of …